Body clock check: a simple swab may guide immunotherapy timing for lung cancer
NCT ID NCT07661251
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these samples. The goal is to see if different chronotypes (early birds vs. night owls) respond better to immunotherapy and whether treatment itself alters the body clock. This is an observational study, meaning no new treatment is given—just monitoring and sample collection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could pave the way for timing immunotherapy doses to match a patient's internal clock, potentially improving treatment effectiveness.
What could go wrong
This is a small observational study, so results may not apply broadly. The TimeTeller tool is new and unproven in this context.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.